# Scienture Holdings Inc. (SCNX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $6M  
**Price:** $0.38 (+7.65%)

> Scienture Holdings operates as a specialty pharmaceutical company through its wholly owned subsidiary Scienture, LLC, focusing on developing and commercializing branded pharmaceutical products for central nervous system and cardiovascular diseases in the United States. The company's current commercial portfolio includes Arbli, an FDA-approved oral suspension formulation of losartan potassium for treating hypertension and related cardiovascular conditions, and REZENOPY, a naloxone nasal spray for emergency opioid overdose treatment. Scienture maintains a pipeline of investigational candidates spanning therapeutic areas including pain management and thrombosis. The company operates through two segments: Scienture, which focuses on branded pharmaceutical development and commercialization, and Integra, which engages in wholesale distribution of licensed pharmaceutical brands, generics, and non-drug products. Scienture has established partnerships with major wholesalers, health plans, and group purchasing organizations to distribute its products across retail, institutional, and long-term care settings. Founded in 2010 and based in the United States, the company leverages intellectual property protection, including patents listed in the FDA Orange Book, to support its specialty pharmaceutical strategy.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $431,609 | $331,482 | -$43M | -$42M | $-2.70 |
| 2024 | $136,643 | $6,005 | -$15M | $9M | $2.48 |
| 2023 | $1M | $49,030 | -$4M | -$18M | $-23.35 |
| 2022 | $10M | $6M | -$3M | -$3M | $-6.13 |
| 2021 | $10M | $5M | -$5M | -$5M | $-0.65 |
| 2020 | $17M | $6M | -$3M | -$3M | — |
| 2019 | $7M | $5M | $125,224 | -$284,428 | $-0.05 |
| 2018 | $4M | $3M | -$87,616 | $9,038 | $0.00 |
| 2017 | $3M | $3M | $395,095 | $288,983 | $0.01 |
| 2016 | $2M | $2M | -$1M | -$3M | $-0.09 |
| 2015 | $3M | $3M | -$137,070 | -$1M | $-0.04 |
| 2014 | $1M | $1M | -$1M | -$2M | $-0.07 |
| 2013 | $955,881 | $11,811 | -$2M | -$2M | $-0.15 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $84M | $14M | $70M | $7M | — |
| 2024 | $105M | $26M | $79M | — | $3M |
| 2023 | $13M | $12M | $542,353 | $361 | — |
| 2022 | $4M | $3M | $763,136 | $1M | — |
| 2021 | $6M | $2M | $4M | $3M | — |
| 2020 | $10M | $1M | $9M | $6M | — |
| 2019 | $6M | $1M | $4M | $3M | $225,000 |
| 2018 | $2M | $1M | $844,668 | $869,557 | $522,052 |
| 2017 | $617,476 | $929,409 | -$311,933 | $183,914 | $666,516 |
| 2016 | $337,124 | $1M | -$1M | $14,679 | — |
| 2015 | $2M | $2M | $267,017 | $78,708 | — |
| 2014 | $1M | $553,677 | $668,441 | $695,817 | — |
| 2013 | $403,867 | $273,002 | $130,865 | $84,317 | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$13M | — | — |
| 2024 | -$14M | $12,000 | -$14M |
| 2023 | -$2M | — | — |
| 2022 | -$2M | — | — |
| 2021 | -$3M | $22,596 | -$3M |
| 2020 | -$2M | $37,505 | -$2M |
| 2019 | $141,775 | — | — |
| 2018 | $273,386 | — | — |
| 2017 | $171,670 | — | — |
| 2016 | -$503,529 | — | — |
| 2015 | $90,386 | — | — |
| 2014 | -$1M | — | — |
| 2013 | -$844,579 | $10,989 | -$855,568 |

Source: [CompaniesByCap](https://companiesbycap.com/company/SCNX)